Cargando…
Secukinumab in severe COVID-19 pneumonia: Does it have a clinical impact?
Autores principales: | Hasan, Md. Jahidul, Rabbani, Raihan, Anam, Ahmad Mursel, Huq, Shihan Mahmud Redwanul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The British Infection Association. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139439/ https://www.ncbi.nlm.nih.gov/pubmed/34029628 http://dx.doi.org/10.1016/j.jinf.2021.05.011 |
Ejemplares similares
-
Therapeutic safety and efficacy of triple-immunosuppressants versus dual-immunosuppressants in severe-to-critical COVID-19: a prospective cohort study in Bangladesh
por: Hasan, Md Jahidul, et al.
Publicado: (2022) -
The Susceptibility of MDR-K. Pneumoniae To Polymyxin B Plus Its Nebulised Form Versus Polymyxin B Alone in Critically Ill South Asian Patients
por: Hasan, Md. Jahidul, et al.
Publicado: (2021) -
Additional baricitinib loading dose improves clinical outcome in COVID-19
por: Hasan, Md Jahidul, et al.
Publicado: (2020) -
Aerosolized Plus Intravenous Polymyxin B Versus Colistin in the Treatment of Pandrug-Resistant Klebsiella Pneumonia-mediated Ventilator-Associated Pneumonia: A Retrospective Cohort Study in Bangladesh
por: Hasan, Md Jahidul, et al.
Publicado: (2023) -
Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh
por: Hasan, Md. Jahidul, et al.
Publicado: (2021)